Search

Author/Creator Costelloe, Lisa

1. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Issue 2 (21st May 2014)

Authors:
Tuohy, Orla; Costelloe, Lisa; Hill-Cawthorne, Grant; Bjornson, Ingunn; Harding, Katharine; Robertson, Neil; May, Karen; Button, Tom; Azzopardi, Laura; Kousin-Ezewu, Onajite; Fahey, Michael T; Jones, Joanne; Compston, D Alastair S; Coles, Alasdair
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 86:Issue 2(2015)
Page Start:
208
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phytocannabinoid‐dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity. (18th January 2021)

Authors:
Damstra‐Oddy, Joseph L.; Warren, Eleanor C.; Perry, Christopher J.; Desfougères, Yann; Fitzpatrick, John‐Mark K.; Schaf, Judith; Costelloe, Lisa; Hind, William; Downer, Eric J.; Saiardi, Adolfo; Williams, Robin S.B.
Journal:
British journal of pharmacology
Issue:
Volume 178:Number 5(2021)
Page Start:
1149
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). Issue 8 (1st March 2007)

Authors:
Costelloe, Lisa; O'Rourke, Killian; Kearney, Hugh; McGuigan, Christopher; Gribbin, Lisa; Duggan, Marguerite; Daly, Leslie; Tubridy, Niall; Hutchinson, Michael
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 78:Issue 8(2007)
Page Start:
841
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗